Avanos Medical/AVNS

$18.70

-0.05%
-
1D1W1MYTD1YMAX

About Avanos Medical

Avanos Medical, Inc. is a medical device company, which is focused on delivering solutions. The Company offers healthcare needs, such as providing nutrition to patients from hospital to home and reducing the use of opioids while helping patients move from surgery to recovery. The Company conducts its business in one segment that provides its medical device products to healthcare providers and patients globally with manufacturing facilities in the United States and Mexico. Its digestive health products include MIC-KEY enteral feeding tubes, Corpak patient feeding solutions and NeoMed neonatal and pediatric feeding solutions. The Company’s acute pain products include ON-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems. The Company's interventional pain solutions include COOLIEF pain therapy and OrthogenRxs knee osteoarthritis pain relief injection products.

Ticker

AVNS

Sector

Healthcare

Trading on

NYSE

Industry

Medical Equipment & Supplies

CEO

Joseph Woody

Employees

3,771

Headquarters

Alpharetta, United States
Website
avanos.com

Avanos Medical Metrics

BasicAdvanced
$870.95M
Market cap
-
P/E ratio
-$1.32
EPS
0.96
Beta
-
Dividend rate
$870.95M
0.9636
$31.31
$17.24
263.92K
2.076
1.38
12.893
13.589
51.698
4.27%
-0.57%
-0.78%
-0.65%
1.294
0.704
4.34
59.654
-1.58%
-145.68%
-1.97%

What the Analysts think about Avanos Medical

Analyst Ratings

Majority rating from 3 analysts.
Hold

Price Targets

Average projection from 2 analysts.
25.67% upside
High $27.00
Low $20.00
$18.70
Current price
$23.50
Average price target

Avanos Medical Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
6.05% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$173.3M
1.17%
Net income
$10.5M
-383.78%
Profit margin
6.05%
-381.4%

Avanos Medical Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 12.73%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$0.27
$0.37
$0.42
$0.32
-
Expected
$0.27
$0.30
$0.28
$0.37
$0.21
Surprise
-1.55%
24.16%
50%
-12.73%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Avanos Medical stock?

Avanos Medical (AVNS) has a market cap of $870.95M as of April 19, 2024.

What is the P/E ratio for Avanos Medical stock?

The price to earnings (P/E) ratio for Avanos Medical (AVNS) stock is 0 as of April 19, 2024.

Does Avanos Medical stock pay dividends?

No, Avanos Medical (AVNS) stock does not pay dividends to its shareholders as of April 19, 2024.

When is the next Avanos Medical dividend payment date?

Avanos Medical (AVNS) stock does not pay dividends to its shareholders.

What is the beta indicator for Avanos Medical?

Avanos Medical (AVNS) has a beta rating of 0.96. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Avanos Medical stock price target?

The target price for Avanos Medical (AVNS) stock is $23.5, which is 25.67% above the current price of $18.7. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Avanos Medical stock

Buy or sell Avanos Medical stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing